Lupin has received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Depakote Extended-Release Tablets, 250 mg and 500 mg, of AbbVie Inc.
Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg (RLD: Depakote ER) had annual sales of approximately $159 million in the U.S. (IQVIA MAT June 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
